Amphastar Pharmaceuticals, Inc. (AMPH) Key Metrics
AMPH valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $1.10B
- Enterprise value
- $1.46B
- P/E (TTM)
- 15.3 10-yr median 19.7
- Forward P/E
- —
- PEG ratio
- 2.77
- Price / sales
- 1.5 10-yr median 3.0
- Price / book
- 1.4 10-yr median 2.6
- EV / EBITDA
- 7.6 10-yr median 21.5
- Dividend yield
- —
- Beta
- 0.90
AMPH key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsAMPH valuation Price multiples at each fiscal year-end price.
AMPH returns How much profit the business earns on the capital it uses.
AMPH per-share figures Results divided by the shares outstanding at year-end.
AMPH financial health Debt, liquidity and how easily interest is covered.
AMPH efficiency & capital use Working capital cycle and where the cash goes.
AMPH valuation history
AMPH returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
AMPH debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
AMPH cash returned to shareholders
AMPH price vs earnings per share
AMPH key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $1.29B | $1.93B | $3.28B | $1.47B | $1.16B | $987.9M | $962.7M | $923.3M | $930.6M | $875.0M |
| Enterprise value | $1.66B | $2.36B | $3.64B | $1.40B | $1.13B | $949.5M | $939.8M | $884.3M | $909.5M | $839.9M |
| P/E ratio | 13.2 | 12.1 | 23.8 | 16.1 | 18.7 | 704.1 | 19.7 | — | 206.4 | 83.1 |
| Price / sales | 1.8 | 2.6 | 5.1 | 2.9 | 2.6 | 2.8 | 3.0 | 3.1 | 3.9 | 3.4 |
| Price / book | 1.6 | 2.6 | 5.1 | 2.8 | 2.6 | 2.5 | 2.5 | 2.8 | 2.8 | 2.7 |
| Price / free cash flow | 10.7 | 11.2 | 22.6 | 22.5 | 16.4 | 42.2 | — | — | 226.4 | 50.9 |
| Price / operating cash flow | 8.3 | 9.1 | 17.9 | 16.5 | 11.8 | 17.3 | 23.1 | 24.2 | 23.7 | 22.7 |
| EV / sales | 2.3 | 3.2 | 5.7 | 2.8 | 2.6 | 2.7 | 2.9 | 3.0 | 3.8 | 3.3 |
| EV / EBITDA | 7.8 | 8.5 | 15.2 | 9.5 | 10.2 | 31.5 | 44.6 | 112.0 | 50.9 | 27.8 |
| EV / free cash flow | 13.7 | 13.7 | 25.1 | 21.4 | 16.0 | 40.6 | — | — | 221.3 | 48.9 |
| Earnings yield | 7.6% | 8.3% | 4.2% | 6.2% | 5.4% | 0.1% | 5.1% | −0.6% | 0.5% | 1.2% |
| Free cash flow yield | 9.4% | 8.9% | 4.4% | 4.4% | 6.1% | 2.4% | 0.0% | −0.9% | 0.4% | 2.0% |
| Dividend yield | — | — | 13.9% | 1.1% | 1.4% | 2.3% | — | 2.2% | 0.0% | 1.2% |
| Shareholder yield (dividends + buybacks) | 5.9% | 4.4% | 15.6% | 3.8% | 3.9% | 4.8% | 2.3% | 4.9% | 3.3% | 2.3% |
| Share price at fiscal year-end | $26.78 | $37.13 | $61.85 | $28.02 | $23.29 | $20.11 | $19.29 | $19.90 | $19.24 | $18.42 |
| Per share | ||||||||||
| Revenue per share | $14.93 | $14.06 | $12.16 | $9.52 | $8.79 | $7.12 | $6.46 | $6.35 | $4.97 | $5.37 |
| Earnings per share | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 | $0.03 | $0.98 | −$0.12 | $0.09 | $0.22 |
| Operating cash flow per share | $3.24 | $4.10 | $3.46 | $1.70 | $1.97 | $1.17 | $0.84 | $0.82 | $0.81 | $0.81 |
| Free cash flow per share | $2.51 | $3.31 | $2.74 | $1.24 | $1.42 | $0.48 | $0.00 | −$0.19 | $0.08 | $0.36 |
| Cash per share | $5.87 | $4.26 | $4.85 | $3.35 | $2.75 | $2.15 | $1.79 | $1.92 | $1.41 | $1.53 |
| Book value per share | $16.36 | $14.07 | $12.06 | $10.08 | $8.95 | $8.19 | $7.64 | $7.17 | $6.97 | $6.93 |
| Tangible book value per share | $4.62 | $2.72 | $0.49 | $9.37 | $8.17 | $7.36 | $6.82 | $6.25 | $6.04 | $5.87 |
| Dividends per share | — | — | $8.57 | $0.30 | $0.32 | $0.47 | — | $0.44 | $0.00 | $0.21 |
| Capex per share | $0.72 | $0.79 | $0.72 | $0.46 | $0.55 | $0.69 | $0.83 | $1.01 | $0.73 | $0.45 |
| Debt per share | $13.61 | $12.50 | $11.77 | $1.96 | $2.10 | $1.37 | $1.33 | $1.08 | $0.97 | $0.79 |
| Shares outstanding | 48.2M | 52.1M | 53.0M | 52.4M | 49.8M | 49.1M | 49.9M | 46.4M | 48.4M | 47.5M |
| Change in shares outstanding | −7.4% | −1.8% | +1.1% | +5.3% | +1.3% | −1.6% | +7.6% | −4.1% | +1.8% | +5.7% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | 12.9% | 23.3% | 23.6% | 18.8% | 14.7% | 0.4% | 13.7% | −1.7% | 1.4% | 3.4% |
| Return on invested capital (ROIC) | 9.6% | 16.0% | 21.9% | 19.7% | 13.6% | 1.5% | −0.0% | −2.2% | −0.3% | 3.9% |
| Return on assets (ROA) | 6.1% | 10.3% | 12.2% | 12.9% | 9.5% | 0.2% | 8.9% | −1.2% | 1.0% | 2.6% |
| Return on tangible assets | 9.2% | 16.2% | 15.3% | 13.0% | 9.8% | 0.2% | 9.0% | −1.2% | 1.1% | 2.8% |
| Free cash flow margin | 16.8% | 23.5% | 22.6% | 13.1% | 16.1% | 6.7% | 0.1% | −2.9% | 1.7% | 6.7% |
| Income quality (OCF / net income) | 1.59 | 1.34 | 1.33 | 0.98 | 1.58 | 40.82 | 0.85 | — | 8.70 | 3.66 |
| Financial health | ||||||||||
| Total debt | $656.0M | $650.5M | $623.6M | $102.6M | $104.7M | $67.3M | $66.6M | $50.2M | $47.2M | $37.7M |
| Cash & short-term investments | $282.8M | $221.6M | $256.8M | $175.8M | $136.7M | $105.6M | $89.5M | $89.2M | $68.2M | $72.9M |
| Net debt | $373.2M | $428.9M | $366.8M | −$73.2M | −$32.0M | −$38.3M | −$22.9M | −$39.0M | −$21.1M | −$35.2M |
| Debt / equity | 0.83 | 0.89 | 0.98 | 0.19 | 0.23 | 0.17 | 0.17 | 0.15 | 0.14 | 0.11 |
| Debt / assets | 0.40 | 0.41 | 0.41 | 0.14 | 0.16 | 0.11 | 0.11 | 0.10 | 0.10 | 0.09 |
| Net debt / EBITDA | 1.76 | 1.55 | 1.53 | −0.50 | −0.29 | −1.27 | −1.09 | −4.94 | −1.18 | −1.16 |
| Current ratio | 4.02 | 3.07 | 2.17 | 3.99 | 3.06 | 2.49 | 2.84 | 2.06 | 2.79 | 3.04 |
| Quick ratio | 2.90 | 2.19 | 1.70 | 2.90 | 2.17 | 1.63 | 1.61 | 1.41 | 1.85 | 1.72 |
| Interest coverage | 5.5 | 6.8 | 7.3 | 58.2 | 79.0 | 29.3 | -0.3 | -35.5 | -1.1 | 15.3 |
| Working capital | $477.9M | $360.3M | $264.2M | $283.5M | $214.3M | $167.5M | $165.2M | $113.5M | $120.6M | $123.5M |
| Invested capital | $1.16B | $1.16B | $1.01B | $455.5M | $413.5M | $364.0M | $358.5M | $293.5M | $316.3M | $294.1M |
| Tangible asset value | $222.8M | $141.6M | $26.1M | $491.4M | $406.7M | $408.1M | $386.4M | $322.1M | $292.2M | $278.9M |
| Net current asset value | −$204.5M | −$311.1M | −$383.9M | $165.0M | $92.1M | $97.2M | $95.8M | $71.1M | $70.4M | $85.6M |
| Graham number | $27.37 | $31.14 | $26.54 | $19.89 | $15.85 | $2.29 | $12.98 | — | $3.82 | $5.88 |
| Graham net-net per share | −$7.50 | −$8.51 | −$9.00 | $1.54 | $0.32 | $0.43 | $0.39 | $0.30 | $0.20 | $0.72 |
| Capital allocation | ||||||||||
| Dividends paid | — | — | $454.1M | $15.7M | $15.9M | $23.2M | — | $20.3M | $0 | $10.2M |
| Share buybacks (net) | $75.6M | $85.5M | $58.1M | $39.9M | $28.9M | $24.4M | $22.3M | $25.0M | $30.7M | $9.9M |
| Dividend payout ratio | — | — | 330.1% | 17.1% | 25.6% | — | — | — | 0.0% | 96.8% |
| Dividends + buybacks / free cash flow | 62.3% | 49.6% | 352.4% | 85.3% | 63.5% | 203.3% | — | — | 748.1% | 117.0% |
| Capex / revenue | 4.8% | 5.6% | 5.9% | 4.8% | 6.3% | 9.7% | 12.9% | 15.9% | 14.6% | 8.4% |
| Capex / operating cash flow | 22.3% | 19.2% | 20.8% | 26.9% | 28.0% | 59.1% | 99.5% | 122.6% | 89.5% | 55.5% |
| Capex / depreciation | 0.55 | 0.72 | 0.91 | 0.85 | 1.08 | 1.34 | 1.97 | 2.83 | 2.22 | 1.47 |
| Stock-based compensation / revenue | 3.8% | 3.3% | 3.1% | 3.6% | 4.3% | 5.9% | 5.4% | 5.7% | 7.1% | 5.9% |
| R&D / revenue | 11.9% | 10.1% | 11.4% | 15.0% | 13.9% | 19.2% | 21.4% | 19.5% | 18.1% | 16.1% |
| SG&A / revenue | 18.0% | 12.9% | 12.5% | 13.3% | 15.7% | 18.6% | 19.6% | 19.7% | 21.2% | 18.5% |
| Efficiency | ||||||||||
| Days sales outstanding | 71.4 | 63.2 | 57.9 | 61.3 | 60.4 | 58.1 | 55.2 | 54.6 | 47.7 | 42.9 |
| Days of inventory on hand | 165.8 | 132.3 | 130.3 | 143.3 | 145.4 | 183.2 | 172.3 | 129.3 | 175.1 | 181.8 |
| Days payables outstanding | 31.7 | 28.5 | 28.6 | 31.2 | 35.7 | 43.7 | 54.0 | 46.6 | 44.7 | 40.9 |
| Cash conversion cycle (days) | 205.6 | 167.0 | 159.6 | 173.4 | 170.1 | 197.7 | 173.5 | 137.2 | 178.2 | 183.9 |
| Receivables turnover | 5.11 | 5.77 | 6.31 | 5.95 | 6.05 | 6.28 | 6.61 | 6.68 | 7.65 | 8.50 |
| Payables turnover | 11.53 | 12.80 | 12.77 | 11.71 | 10.22 | 8.36 | 6.75 | 7.83 | 8.17 | 8.93 |
| Inventory turnover | 2.20 | 2.76 | 2.80 | 2.55 | 2.51 | 1.99 | 2.12 | 2.82 | 2.08 | 2.01 |
| Asset turnover | 0.45 | 0.47 | 0.57 | 0.71 | 0.67 | 0.57 | 0.59 | 0.61 | 0.54 | 0.62 |
| Average receivables | $140.8M | $126.8M | $102.1M | $83.8M | $72.4M | $55.7M | $48.8M | $44.1M | $31.4M | $30.0M |
| Average payables | $31.6M | $28.0M | $23.0M | $21.4M | $23.3M | $24.7M | $28.2M | $24.0M | $18.3M | $16.9M |
| Average inventory | $165.3M | $129.8M | $104.7M | $98.2M | $94.8M | $103.7M | $89.9M | $66.5M | $71.7M | $75.2M |
| Intangibles / total assets | 34.7% | 37.4% | 40.5% | 5.0% | 5.8% | 6.4% | 7.0% | 8.2% | 9.9% | 11.8% |
Computed from AMPH's annual financial statements (latest annual report filed February 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
AMPH valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Amphastar Pharmaceuticals traded at 13.2 times earnings, against a 10-year median of 19.7. Based on the latest twelve months, the trailing P/E is 15.3. Amphastar Pharmaceuticals earned a return on equity of 12.9% and a return on invested capital of 9.6% in fiscal 2025. It ended the year with $656.0 million of debt and $282.8 million in cash and short-term investments, net debt of $373.2 million. It returned $75.6 million to shareholders: $0 in dividends and $75.6 million in share buybacks, 62% of free cash flow.
See the AMPH income statement, the AMPH chart for price history, or the AMPH stock overview for the latest quote and news.
AMPH key metrics FAQ
What is Amphastar Pharmaceuticals's P/E ratio?
Amphastar Pharmaceuticals's trailing P/E ratio is 15.3 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was 13.2, compared with a 10-year median of 19.7.
What is Amphastar Pharmaceuticals's EV/EBITDA?
Amphastar Pharmaceuticals's enterprise value was 7.8 times EBITDA at the end of fiscal 2025 (enterprise value $1.7 billion, EBITDA $212.3 million); the current EV/EBITDA is 7.6.
What is Amphastar Pharmaceuticals's return on equity?
Amphastar Pharmaceuticals's return on equity (ROE) was 12.9% in fiscal 2025: net income of $98.1 million on average shareholders' equity of $760.6 million.
What is Amphastar Pharmaceuticals's ROIC?
Amphastar Pharmaceuticals's return on invested capital was 9.6% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals had total debt of $656.0 million at the end of fiscal 2025, a debt-to-equity ratio of 0.83 and $373.2 million of net debt (1.76 times EBITDA).
Does Amphastar Pharmaceuticals buy back its shares?
Yes. Amphastar Pharmaceuticals spent $75.6 million on net share repurchases in fiscal 2025 Shares outstanding changed −7.4% over the year, to 48.2M..
What is Amphastar Pharmaceuticals's free cash flow yield?
Amphastar Pharmaceuticals generated $121.2 million of free cash flow in fiscal 2025, a free cash flow yield of 9.4% on its market value at year-end ($1.3 billion).
What is Amphastar Pharmaceuticals's current ratio?
Amphastar Pharmaceuticals's current ratio was 4.02 at the end of fiscal 2025: current assets were 4.02 times current liabilities.